Astek Diagnostics
Astek Diagnostics, based in Baltimore, MD, is a healthcare company specializing in the development of the JIDDU system, a rapid diagnostic platform for detecting UTIs and determining antibiotic sensitivity.
Company History
Astek Diagnostics, formerly known as Astek Diagnostics LLC, was founded in response to Mustafa Al Adhami, PhD's personal experience with antibiotic-resistant UTIs. The company is located in Baltimore, MD, USA, and operates within the healthcare diagnostics industry. Astek Diagnostics participated in the Y-Combinator S21 batch, positioning itself to leverage accelerator resources for rapid development.
Services
Astek Diagnostics is developing the JIDDU system, a clinical diagnostics platform aimed at detecting urinary tract infections (UTIs) and indicating antibiotic sensitivity within one hour. This service focuses on improving diagnostic speed and accuracy, reducing patient complications, and lowering healthcare costs. It is particularly significant for FemHealth due to the higher prevalence of UTIs in women.
Products
The company's current major development is the JIDDU system, which is designed to provide quick and reliable diagnostics for UTIs. Eventually, the system aims to test four different sample types: urine, cerebrospinal fluid (CSF), effluent, and blood. At present, the JIDDU system is focused on urine sample testing, with plans to extend to other sample types.
Market Focus
Astek Diagnostics aims for market entry in 2025. The company is developing partnerships with The University of Maryland Medical Center and MedStar Health, aiming to bring the JIDDU system to a wider audience. The initial focus is on the U.S. market, particularly addressing the needs within the FemHealth sector.
Locations
Astek Diagnostics is headquartered in Baltimore, MD, USA. The company operates across various regions, including the United States, America/Canada, and engages in both remote and partly remote work practices. This geographic flexibility aids in attracting diverse talent and facilitating universal access to their diagnostic solutions.
